KMS-28BMHomo sapiens (Human)Cancer cell line

Also known as: Kawasaki Medical School-28-Bone Marrow, KMS28, KMS-28, KMS28BM, KMS-28-BM

🤖 AI SummaryBased on 11 publications

Quick Overview

Human multiple myeloma cell line with B-cell origin, used in cancer research.

Detailed Summary

KMS-28BM is a human multiple myeloma cell line derived from a B-cell lineage. It is widely utilized in cancer research, particularly in studies involving multiple myeloma. This cell line is known for its specific genetic characteristics, including translocations and mutations that are relevant to myeloma pathogenesis. Research on KMS-28BM has contributed to understanding the molecular mechanisms underlying myeloma progression and therapeutic responses. The cell line is also used to study the effects of various treatments and to identify potential biomarkers for disease management.

Research Applications

Multiple myeloma researchGenetic and molecular studiesDrug response profiling

Key Characteristics

B-cell originTranslocations and mutations associated with myelomaUsed in studying tumor biology and therapeutic responses
Generated on 6/19/2025

Basic Information

Database IDCVCL_2994
SpeciesHomo sapiens (Human)
Tissue SourceBone marrow[UBERON:UBERON_0002371]

Donor Information

Age77
Age CategoryAdult
SexFemale
Raceasian

Disease Information

DiseaseMultiple myeloma
LineageLymphoid
SubtypePlasma Cell Myeloma
OncoTree CodePCM

DepMap Information

Source TypeHSRRB
Source IDACH-000419_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Gly105Arg (c.313G>C)Homozygous-Unknown
MutationSimpleKRASp.Gly12Ala (c.35G>C)Unspecified-PubMed=21173094

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
11
D16S539
9,11
D18S51
14,15
D21S11
30
D3S1358
16
D5S818
14
D7S820
8,11
D8S1179
10,11
FGA
20,23
Penta D
9,11
Penta E
12,15
TH01
7,9.3
TPOX
8,9
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.

Sirota M., Wiita A.P.

Leukemia 34:2754-2765(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.

Todoerti K., Ronchetti D., Lambertenghi-Deliliers G., Neri A.

Genes Chromosomes Cancer 48:521-531(2009).

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

Fabris S., Lambertenghi-Deliliers G., Neri A.

BMC Med. Genomics 1:37.1-37.9(2008).

Characterization of MYC translocations in multiple myeloma cell lines.

Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.

J. Natl. Cancer Inst. Monogr. 39:25-31(2008).

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Stewart A.K., Carpten J.D., Bergsagel P.L.

Cancer Cell 12:131-144(2007).

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Lambertenghi-Deliliers G., Bertoni F., Neri A.

Genes Chromosomes Cancer 46:226-238(2007).

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Taniwaki M., Inazawa J.

Am. J. Pathol. 165:71-81(2004).

Web Resources